LGND News and Press, Ligand Pharmaceuticals Incorporated From 12/30/22

Summary Ligand's spinoff of OmniAb has rightsized Ligand as it faces revenue challenges. Ligand's management changes should be productive for it. Several key catalysts are poised to enhance its portfolio to address expected revenue reductions. My inaugural Ligand (LGND) ...

Executive Management Reviewed Business Model and Growth Drivers Following the Successful Spin-Off of OmniAb, Introduced 2023 Financial Guidance Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that at today’s Investor and Analyst Day event its executive management...

COLUMBUS, Ohio, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced that it will share a poster presentation a...

John Higgins Retires as CEO and will Resign from the Ligand Board of Directors Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that John Higgins has retired as Chief Executive Officer, effective as of today, and that the company’s board of directors has nam...

3 Hot Penny Stocks To Buy For Under $3, Worth It? Penny stocks are some of the most volatile assets in the stock market today. But is the risk worth the reward? That’s something traders grapple with daily. One unique thing about 2022 is that there are far more companies with shar...

COLUMBUS, Ohio, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative targeted therapeutics to specifically treat ESR1 -mutated metastatic breast and gynecological cancers, today announced that it had four abstr...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it will hold an Investor and Analyst Day at The St. Regis New York on December 13, 2022, from 11:00 a.m. to 12:30 p.m. Eastern time (8:00 a.m. to 9:30 a.m. Pacific time). A live and archived webcast will be avai...

October CPI Data Is Out & These Penny Stocks Are Ripping Higher If you’re looking for penny stocks to buy, the trend is your friend, as they say. Now that October’s CPI inflation data is out, the market has reacted, and the bulls are trying to take control. General...

Ligand Pharma ( NASDAQ: LGND ) is trading ~16% higher after the company forecast 2022 revenue above estimates, due to higher sales Kyprolis, Rylaze and Teriparatide. The company raised 2022 total revenue of $184M to $189M, compared to previous guidance of $133M to ...

Ligand Pharmaceuticals, Inc. (LGND) Q3 2022 Earnings Conference Call November 07, 2022, 04:30 PM ET Company Participants Simon Latimer - Head, IR John Higgins - CEO Matthew Korenberg - President & CFO Octavio Espinoza - CFO Conference Call Participa...